Drug Profile
Research programme: NMDA receptor antagonists - Neurotune
Alternative Names: BND-003; BND-13317; BND-3; NiK 003; Nik-003; NiK-13317; NT-13317; NT-24336Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NiKem Research
- Developer Neurotune
- Class Lactams
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic neuropathies; Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-neuropathies in Switzerland
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in Switzerland (PO)
- 03 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the adverse events and Pain pharmacodynamics section